Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
NCT Number: NCT07647692
Pulmonary ground-glass nodules (GGNs) are commonly found on chest CT scans. Some stay stable for years, while others slowly or rapidly turn into lung cancer. Doctors currently follow these nodules with repeated CT scans, but it is difficult to tell ahead of time which nodules will progress, how fast they will progress, and which ones can be safely monitored rather than immediately treated.
This observational study aims to develop and validate an artificial intelligence (AI) model that uses each patient's series of CT scans over time to predict the long-term growth behavior of a GGN. The research team will collect three retrospective single-center cohorts from Peking University People's Hospital (a development cohort and two internal test cohorts, one from surgically resected patients and one from non-operated patients followed by serial CT) as well as a prospective multi-center validation cohort enrolled after the AI model is locked.
For every patient, each GGN is automatically segmented in three dimensions on every CT scan. A deep learning model extracts imaging features at each timepoint and feeds the sequence of features, together with the actual times between scans, into a time-aware sequence model. The model is trained to predict (i) whether the nodule will show radiological progression at 1, 3, and 5 years after baseline, and (ii) which of four long-term growth patterns the nodule will follow: stable, slow progression, slow-then-rapid progression, or rapid progression. In patients who were ultimately resected, the histopathological diagnosis serves as a secondary reference standard.
This is an observational study. No experimental treatment is given. All CT scans and clinical visits are part of routine clinical care.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Beijing, Beijing Municipality, 100044, China
Pulmonary ground-glass nodules (GGNs), including pure ground-glass nodules (pGGN) and mixed ground-glass nodules (mGGN), span a biological spectrum from atypical adenomatous hyperplasia and adenocarcinoma in situ to invasive lung adenocarcinoma. Current management guidelines (Fleischner Society, BTS, NCCN) rely primarily on cross-sectional CT features (diameter, density, consolidation-to-tumor ratio); these features do not capture the non-linear long-term behavior of GGNs. Long-term cohorts show that a meaningful fraction of GGNs remain indolent for years and then accelerate, demonstrating the limits of single-timepoint assessment.
Existing GGN management algorithms emphasize cross-sectional features measured on a single CT scan. Cross-sectional features alone are known to lose discriminative performance at longer (3-5 year) prediction horizons, where the relevant signal is increasingly carried by how the nodule changes over time rather than how it looks at any single moment. The present study is designed around this observation. It shifts the modeling target from static single-CT classification to a long-term spatiotemporal deep-learning framework that explicitly encodes the full trajectory of the nodule across the entire available serial-CT record.
This study uses a mixed retrospective-prospective design and is reported under TRIPOD guidance. Four cohorts are pre-specified:
After resampling to 1 × 1 × 1 mm and lung-window normalization, serial CTs are spatiotemporally registered (rigid + deformable) to baseline. For each timepoint, two regions of interest (ROIs) are derived for every target GGN: (i) the intratumoral ROI, defined as the full 3D extent of the nodule itself, automatically segmented using a pre-trained 3D U-Net with expert review; and (ii) the peritumoral ROI, defined as the shell of lung parenchyma extending 5 mm outward from the segmented nodule boundary, with intervening vessels, airways, and pleural surfaces masked out, to capture the perinodular lung microenvironment around the nodule. Radiomic features (per the Image Biomarker Standardization Initiative, IBSI) are extracted separately from each ROI, and deep features are extracted by a 3D convolutional neural network (e.g., 3D ResNet) applied independently to the intratumoral and peritumoral volumes. The two feature streams are concatenated at each timepoint to capture both intra-lesional heterogeneity and the perilesional microenvironment, which prior work from our team has shown to be informative.
The ordered sequence of per-timepoint feature vectors, together with the actual inter-scan time intervals, is fed into a time-aware sequence model (LSTM, GRU, or continuous-time Transformer) to model growth dynamics. Clinical covariates (age, sex, smoking history, family history of malignancy, emphysema score) are fused into a multimodal network. Temporal-attention maps and Shapley values are used for interpretability, with separate attribution reported for the intratumoral and peritumoral feature streams.
Model performance is reported with AUC and 95% CI for binary 1-, 3-, and 5-year progression endpoints, with DeLong testing against a single-baseline-CT radiomics benchmark; multi-class performance for the four-pattern trajectory task is reported with weighted / macro / micro F1 plus per-class precision and recall. Class imbalance, in particular the slow-then-rapid subgroup, is addressed with ADASYN oversampling and focal loss. For the subset of patients ultimately resected (Cohorts 1, 2, and the operated subset of Cohort 4), histopathological diagnosis serves as a secondary reference standard against which the imaging endpoints and the AI-predicted trajectory are compared.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Cohort-specific inclusion
Exclusion criteria
Routine-care thin-slice non-contrast chest CT (slice thickness ≤ 1.5 mm, lung-window reconstruction) acquired at baseline and at subsequent clinical follow-up timepoints (minimum inter-scan interval > 1 month). Images are resampled to 1 × 1 × 1 mm and intensity-normalized before analysis. No additional imaging, radiation exposure, or procedures are performed for this study; all imaging is part of routine clinical care.
Time frame: 12 months from baseline CT (± 3-month window)
Radiological progression is defined as meeting either of the following on a follow-up thin-slice CT compared with the baseline CT, based on 3D automated segmentation with expert adjudication: (a) increase of the overall maximum diameter of the nodule by ≥ 2 mm; OR (b) the appearance of a new solid component, or the increase in maximum diameter of an existing solid component, by ≥ 2 mm. The solid component is defined as regions with an attenuation value greater than -300 HU. Each participant is classified as a progression event at the 1-year timepoint if either criterion is met on a CT performed within the ± 3-month window around 12 months after baseline. Applies to all four cohorts.
Time frame: 36 months from baseline CT (± 6-month window)
Same progression definition as Primary Outcome 1, assessed on a CT performed within the ± 6-month window around 36 months after baseline. Ascertained where the available follow-up duration permits. Applies to all four cohorts.
Time frame: 60 months from baseline CT (± 6-month window)
Same progression definition as Primary Outcome 1, assessed on a CT performed within the ± 6-month window around 60 months after baseline. Ascertained where the available follow-up duration permits. Applies to all four cohorts.
Time frame: Assessed across the full serial CT record, up to 60 months from baseline
Each participant's target GGN is assigned, based on the full serial CT record, to exactly one of four mutually exclusive trajectory classes: (1) Stable - no progression event during follow-up; (2) Slow progression - continuous, approximately constant slow growth or slow increase of the solid component; (3) Slow-then-rapid progression - stable or minimally changing for an early period (e.g., 1-3 years) followed by abrupt acceleration (e.g., marked shortening of volume doubling time or new prominent solid component); (4) Rapid progression - aggressive growth evident early in follow-up. Classification is performed by two senior chest radiologists reading independently on the 3D automated outputs, with a third senior radiologist adjudicating disagreements.
Time frame: At the time of clinical surgical resection (varies by participant; up to 60 months from baseline)
For participants who undergo surgical resection of the target GGN as part of routine clinical care (all participants in Group 1, all in Group 2, and the operated subset of Group 4), the histopathological diagnosis of the resected specimen is recorded from the routine clinical pathology report and used as a secondary reference standard. Diagnoses are categorized per the WHO Classification of Lung Tumors as: atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), invasive adenocarcinoma (IAC), or other benign / non-adenocarcinoma diagnoses. Concordance between AI-predicted trajectory class and final histopathology is reported.
Contact information is provided by the study sponsor or research team.
Peking University People's Hospital
Other
Development and Multi-Cohort Validation of a Deep Learning Spatiotemporal Model for Predicting Long-Term Progression of Pulmonary Ground-Glass Nodules Using Serial Thoracic CT
Acronym: GGN-Trajectory
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07395375
Lung Diseases, Lung Neoplasms
Guangzhou, China
View Trial DetailsNCT07595120
Early-Stage Lung Cancer, Lung Diseases
Shanghai, China
View Trial DetailsNCT07277088
Disease, Lung Cancer (Diagnosis)
Shanghai, China
View Trial DetailsNCT06685458
Lung Cancer, Lung Diseases
View Trial Details